Evidence map›Paper›PMID 36542826›Full record

Trial reportBlood2023

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.

Jeremy S Abramson, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri and 8 more

2 registry-linked trialsOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 258 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
258citing papers in PubMed, 8 pooled it
32.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03575351 phase3completednot on this map

A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM).

TypeinterventionalSponsorCelgeneRan2018 to 2023Enrolled184ConditionsLymphoma, Non-HodgkinArmsStandard of Care, JCAR017
NCT06339255 recruitingnot on this map

A Multicenter Prospective Observational Study on Chimeric Antigen Receptor (CAR) T-cell Therapy for Lymphoma: Monitoring Feasibility, Efficacy, Toxicity and Biomarkers in a Real Life Setting

TypeobservationalSponsorPaolo CorradiniRan2019 to 2029Enrolled5,300ConditionsDiffuse Low Grade B-Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Mantle Cell Lymphoma, Follicular Lymphoma
3 · Its place in the literature

Who cites it

258 citing papers in PubMed, 8 syntheses or guidelines pooled it, 337 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Trial
  13. Trial
  14. Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

198 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 16 institutions in 7 countries.

Jeremy S AbramsonMassachusetts General Hospital Cancer Center, Harvard Medical School, Harvard University, Boston, MA.ORCID 0000-0001-8467-9257
Scott R SolomonTransplant and Cellular Immunotherapy Program, Northside Hospital Cancer Institute, Atlanta, GA.
Jon ArnasonDepartment of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA.
Patrick B JohnstonDivision of Hematology, Mayo Clinic, Rochester, MN.
Bertram GlassDepartment of Hematology and Cell Therapy, Helios Klinikum Berlin-Buch, Berlin, Germany.
Veronika BachanovaDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN.
Sami IbrahimiTransplant and Cellular Therapy Clinic, University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK.
Stephan MielkeDepartments of Laboratory Medicine and Medicine at Huddinge, Center of Allogeneic Stem Cell Transplantation and Cellular Therapy, Karolinska Institutet and University Hospital, Karolinska Comprehensive Cancer Center, Stockholm, Sweden.ORCID 0000-0002-8325-9215
Pim MutsaersDepartment of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Francisco Hernandez-IlizaliturriDepartment of Hematologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Koji IzutsuDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Franck MorschhauserCentre Hospitalier Universitaire de Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.ORCID 0000-0002-3714-9824
Matthew LunningHematology/Oncology Division, University of Nebraska Medical Center, Omaha, NE.
Alessandro CrottaCelgene, a Bristol-Myers Squibb Company, Boudry, Switzerland.
Sandrine MontheardCelgene, a Bristol-Myers Squibb Company, Boudry, Switzerland.
Alessandro PrevitaliCelgene, a Bristol-Myers Squibb Company, Boudry, Switzerland.
Ken OgasawaraBristol Myers Squibb, Princeton, NJ.ORCID 0000-0002-4264-8927
Manali KamdarDivision of Hematology, Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Aurora, CO.
Bristol-Myers Squibb (Switzerland) · CHBeth Israel Deaconess Medical Center · USBristol-Myers Squibb (United States) · USCentre Hospitalier Universitaire de Lille · FRErasmus MC · NLHarvard University · USHelios Hospital Berlin-Buch · DEKarolinska Institutet · SEMayo Clinic · USNorthside Hospital · USRoswell Park Comprehensive Cancer Center · USTokyo National Hospital · JPUniversity of Colorado Cancer Center · USUniversity of Minnesota · USUniversity of Nebraska Medical Center · USUniversity of Oklahoma · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This global phase 3 study compared lisocabtagene maraleucel (liso-cel) with a standard of care (SOC) as second-line therapy for primary refractory or early relapsed (≤12 months) large B-cell lymphoma (LBCL). Adults eligible for autologous stem cell transplantation (ASCT; N = 184) were randomly assigned in a 1:1 ratio to liso-cel (100 × 106 chimeric antigen receptor-positive T cells) or SOC (3 cycles of platinum-based immunochemotherapy followed by high-dose chemotherapy and ASCT in responders). The primary end point was event-free survival (EFS). In this primary analysis with a 17.5-month median follow-up, median EFS was not reached (NR) for liso-cel vs 2.4 months for SOC. Complete response (CR) rate was 74% for liso-cel vs 43% for SOC (P < .0001) and median progression-free survival (PFS) was NR for liso-cel vs 6.2 months for SOC (hazard ratio [HR] = 0.400; P < .0001). Median overall survival (OS) was NR for liso-cel vs 29.9 months for SOC (HR = 0.724; P = .0987). When adjusted for crossover from SOC to liso-cel, 18-month OS rates were 73% for liso-cel and 54% for SOC (HR = 0.415). Grade 3 cytokine release syndrome and neurological events occurred in 1% and 4% of patients in the liso-cel arm, respectively (no grade 4 or 5 events). These data show significant improvements in EFS, CR rate, and PFS for liso-cel compared with SOC and support liso-cel as a preferred second-line treatment compared with SOC in patients with primary refractory or early relapsed LBCL. This trial was registered at www.clinicaltrials.gov as #NCT03575351.

Indexed as

Hematopoietic Stem Cell TransplantationLymphoma, Large B-Cell, DiffuseAdultAntigens, CD19Antineoplastic Combined Chemotherapy ProtocolsHumansImmunotherapy, AdoptiveProportional Hazards ModelsTransplantation, AutologousAntigens, CD19

Identifiers

PMID36542826
PMCPMC10646768
OpenAlexW4312094698

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.